The First Biosimilar Drug in Breast Cancer Will Contribute 130 Million TL to the Capital Budget Per Year

Abdi Ibrahim, the leader of the Turkish pharmaceutical industry, has launched the first biosimilar product with the active ingredient Trastuzumab, which is now used in breast cancer among women. The product, which is also covered by the Ministry of Health, will provide a public contribution of 130 million TL in a year. The product that prevents the growth of tumor mass in patients with breast cancer will be the first biosimilar monoclonal antibody to be used by medical oncology.

HG

Related Post

thumbnail
hover

9 Useful Habits for Healthy Skin

The skin, the body’s largest organ, is an important barrier for the protection of the internal system. Anadolu Medical Center Dermatol...

  • Posted by HG
thumbnail
hover

İstanbul Airport Opened

İstanbul Airport which will be the world’s largest and most modern airport when completed with 6 independent airfield, 500 aircraft c...

  • Posted by HG
thumbnail
hover

Cataract Surgery Project in Sudan from...

The Turkish Red Crescent launched a new project. The Turkish Red Crescent has started Cataract Surgery Project in Sudan where cataract cases...

  • Posted by HG